Mean Heart Dose Is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiation Therapy
Katelyn M. Atkins(Brigham and Women's Hospital), Raymond H. Mak(Brigham and Women's Hospital), Udo Hoffmann(Massachusetts General Hospital), Danielle S. Bitterman(Brigham and Women's Hospital), Tafadzwa L. Chaunzwa(Dana-Farber Cancer Institute), David Kozono(Dana-Farber Cancer Institute), Balaji Tamarappoo(Cedars-Sinai Medical Center), Hugo J.W.L. Aerts(Maastro Clinic), Elizabeth H. Baldini(Dana-Farber Cancer Institute), Anju Nohria(Brigham and Women's Hospital)
International Journal of Radiation Oncology*Biology*Physics
March 10, 2021
Cited by 70
Related Papers
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque
|Circulation|2020|535
Arterial Inflammation in Patients With HIV
|JAMA|2012|460